Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Heron Therapeutics (HRTX) over the last 11 years, with Q3 2025 value amounting to $48.5 million.

  • Heron Therapeutics' Other Accumulated Expenses rose 1911.49% to $48.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.5 million, marking a year-over-year increase of 1911.49%. This contributed to the annual value of $41.8 million for FY2024, which is 23.89% down from last year.
  • Latest data reveals that Heron Therapeutics reported Other Accumulated Expenses of $48.5 million as of Q3 2025, which was up 1911.49% from $46.2 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Other Accumulated Expenses ranged from a high of $52.4 million in Q2 2023 and a low of $24.7 million during Q1 2021
  • Over the past 5 years, Heron Therapeutics' median Other Accumulated Expenses value was $40.3 million (recorded in 2023), while the average stood at $38.6 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first crashed by 2368.38% in 2021, then skyrocketed by 5820.46% in 2023.
  • Quarter analysis of 5 years shows Heron Therapeutics' Other Accumulated Expenses stood at $25.9 million in 2021, then soared by 49.09% to $38.6 million in 2022, then grew by 8.57% to $41.9 million in 2023, then decreased by 0.24% to $41.8 million in 2024, then increased by 16.15% to $48.5 million in 2025.
  • Its Other Accumulated Expenses stands at $48.5 million for Q3 2025, versus $46.2 million for Q2 2025 and $47.4 million for Q1 2025.